{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:19:22Z","timestamp":1782861562736,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sumitomo Pharma America Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.urology.2025.08.051","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T06:08:46Z","timestamp":1756706926000},"page":"150-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial"],"prefix":"10.1016","volume":"206","author":[{"given":"Kenneth M.","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Owens-Grillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Staskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Rovner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Mujais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2025.08.051_bib1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2010.08.039","article-title":"National community prevalence of overactive bladder in the United States stratified by sex and age","volume":"77","author":"Coyne","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.08.051_bib2","article-title":"Prevalence and trends in overactive bladder among men in the United States, 2005\u20132020","volume":"14","author":"Cheng","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.urology.2025.08.051_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2025.08.051_bib4","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0022-5347(05)65982-4","article-title":"Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings","volume":"166","author":"Hyman","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.08.051_bib5","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/JU.0000000000002183","article-title":"Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I\u2013initial work-up and medical management","volume":"206","author":"Lerner","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.08.051_bib6","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/nau.24348","article-title":"Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: a retrospective observational study","volume":"39","author":"Burnett","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2025.08.051_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JU.0000000000003985","article-title":"The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder","volume":"212","author":"Cameron","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.08.051_bib8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.urology.2015.09.025","article-title":"Real-world patterns of care for the overactive bladder syndrome in the United States","volume":"87","author":"Goldman","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.08.051_bib9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.urology.2009.07.1325","article-title":"Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review","volume":"75","author":"Bartoli","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.08.051_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.urology.2016.07.013","article-title":"The relationship between anxiety and overactive bladder or urinary incontinence symptoms in the clinical population","volume":"98","author":"Lai","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.08.051_bib11","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","article-title":"Patient-reported reasons for discontinuing overactive bladder medication","volume":"105","author":"Benner","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2025.08.051_bib12","series-title":"GEMTESA\u00ae: vibegron","year":"2025"},{"key":"10.1016\/j.urology.2025.08.051_bib13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/JU.0000000000003999","article-title":"Efficacy and safety of vibegron for persistent symptoms of overactive bladder in men being pharmacologically treated for benign prostatic hyperplasia: results from the phase 3 randomized controlled COURAGE trial","volume":"212","author":"Staskin","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.08.051_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2307\/2530643","article-title":"Estimation of a common effect parameter from sparse follow-up data","volume":"41","author":"Greenland","year":"1985","journal-title":"Biometrics"},{"key":"10.1016\/j.urology.2025.08.051_bib15","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/JU.0000000000000807","article-title":"International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR","volume":"204","author":"Staskin","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.08.051_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13937","article-title":"Vibegron improves quality-of-life measures in patients with overactive bladder: patient-reported outcomes from the EMPOWUR study","volume":"75","author":"Frankel","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.urology.2025.08.051_bib17","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s12325-021-01972-8","article-title":"Interpretation of the meaningfulness of symptom reduction with vibegron in patients with overactive bladder: analyses from EMPOWUR","volume":"39","author":"Frankel","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.urology.2025.08.051_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1359105314522084","article-title":"The psychological impact of overactive bladder: a systematic review","volume":"21","author":"Kinsey","year":"2016","journal-title":"J Health Psychol"},{"key":"10.1016\/j.urology.2025.08.051_bib19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2012.04.004","article-title":"Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS","volume":"80","author":"Milsom","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.urology.2025.08.051_bib20","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s12325-019-0880-8","article-title":"Characterizing the health-related quality of life burden of overactive bladder using disease-specific patient-reported outcome measures: a systematic literature review","volume":"36","author":"Johnston","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.urology.2025.08.051_bib21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000497282","article-title":"Effects of mirabegron on anxiety and depression in female patients with overactive bladder","volume":"102","author":"Kinjo","year":"2019","journal-title":"Urol Int"},{"key":"10.1016\/j.urology.2025.08.051_bib22","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0022-5347(01)66780-6","article-title":"Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?","volume":"154","author":"Barry","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2025.08.051_bib23","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.juro.2006.03.088","article-title":"Determining the importance of change in the overactive bladder questionnaire","volume":"176","author":"Coyne","year":"2006","journal-title":"J Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525008295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429525008295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T01:15:17Z","timestamp":1772846117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429525008295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":23,"alternative-id":["S0090429525008295"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2025.08.051","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE Trial","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2025.08.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}